Limula: a platform to streamline cell therapy manufacturing, from R&D to the clinic

Limula is addressing the challenges of clinical centres and biotech companies looking for a solution enabling fully automated production of cell therapies at the point-of-care. We have reimagined how to manipulate cells ex vivo from the ground up, designing our solution with the particularities of autologous treatments in mind from the beginning.

The key value proposition of our unique approach to process automation is in the ability to streamline the transition between R&D and GMP, with a technology that is implemented in two products. LimGROW is a simple research tool that is straight-forward to adopt and does not require significant investment, allowing to derisk key unit operations without building complexity. When the process is ripe for automation, all the learnings can be seamlessly and intuitively transfered into LimONE, a fully automated device supporting end-to-end production. It is now well accepted that combining multiple steps of complex manufacturing processes in a single instrument can significantly decrease treatment production costs by reducing the need for manual labour, multiple pieces of equipment and complex infrastructure.

On top of automation, Limula delivers ease of use, to facilitate adoption and reduce stress on the workforce, but also versatility, to accommodate a variety of workflows and enable different cell therapy products.